Inactive Instrument

News Zynerba Pharmaceuticals, Inc.

Equities

ZYNE

US98986X1090

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE - Zynerba	23-10-12	AQ
Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index	23-10-12	CI
Harmony Biosciences Holdings Completes Acquisition of Zynerba Pharmaceuticals	23-10-11	MT
Zynerba Pharmaceuticals : Acquisition/Asset Disposal - Form 8-K	23-10-11	PU
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE	23-10-11	PR
Fragile X Syndrome Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	23-10-10	AQ
Harmony Biosciences Holdings, Inc. completed the acquisition of Zynerba Pharmaceuticals, Inc..	23-10-09	CI
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions - Zynerba	23-10-05	AQ
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions	23-10-04	GL
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares before 5:00 PM New York City Time, on Tuesday October 10, 2023	23-10-02	AQ
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 - Zynerba	23-09-29	AQ
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023	23-09-29	GL
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index	23-09-28	CI
Harmony Biosciences Says its Xylophone Acquisition Unit Extends Tender Offer for Zynerba Pharmaceuticals to Oct. 10	23-09-27	MT
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.	23-09-27	PR
Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)	23-09-18	AQ
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium	23-09-14	GL
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE	23-09-05	BU
Shareholder Alert: Ademi LLP investigates whether Zynerba Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Harmony	23-08-28	PR
Thinking about buying stock in Zynerba Pharmaceuticals, Taysha Gene Therapies, Novo Integrated Sciences, Design Therapeutics, or Limbach Holdings?	23-08-17	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Zynerba Pharmaceuticals, Inc.

Equities

ZYNE

US98986X1090

Summary

Filters